Avrobio Inc (AVRO)
US Market

Avrobio Stock Analysis & Ratings

AVRO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.74 - $9.37
Previous Close$0.92
Average Volume (3M)454.79K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-0.3
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Avrobio’s price range in the past 12 months?
Avrobio lowest stock price was $0.74 and its highest was $9.37 in the past 12 months.
    What is Avrobio’s market cap?
    Currently, no data Available
    What is Avrobio’s price target?
    The average price target for Avrobio is $5.33. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $6.00 ,the lowest forecast is $4.00. The average price target represents 479.28% Increase from the current price of $0.92.
      What do analysts say about Avrobio?
      Avrobio’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
        When is Avrobio’s upcoming earnings report date?
        Avrobio’s upcoming earnings report date is Aug 11, 2022 which is in 37 days.
          How were Avrobio’s earnings last quarter?
          Avrobio released its earnings results on May 10, 2022. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.582 by -$0.098.
            Is Avrobio overvalued?
            According to Wall Street analysts Avrobio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Avrobio pay dividends?
              Avrobio does not currently pay dividends.
              What is Avrobio’s EPS estimate?
              Avrobio’s EPS estimate is -$0.57.
                How many shares outstanding does Avrobio have?
                Avrobio has 43,696,470 shares outstanding.
                  What happened to Avrobio’s price movement after its last earnings report?
                  Avrobio reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.582. Following the earnings report the stock price went up 1.22%.
                    Which hedge fund is a major shareholder of Avrobio?
                    Among the largest hedge funds holding Avrobio’s share is GMT Capital Corp. It holds Avrobio’s shares valued at 3M.


                      Avrobio Stock Analysis

                      The Avrobio stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Avrobio Inc

                      Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.

                      Similar Stocks
                      Price & Change
                      Magenta Therapeutics
                      Homology Medicines
                      Meiragtx Holdings
                      Autolus Therapeutics

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis